ArticleFrontiers in medicine2026
Prevalence of financial toxicity and construction of a risk prediction model for lung cancer patients at 6 months after discharge.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the prevalence of 6-month post-discharge financial toxicity in lung cancer patients, identify its independent predictors, and establish a valid risk prediction model integrating socioeconomic, clinical, and patient-reported outcome variables as baseline predictors, so as to support early financial toxicity screening, targeted financial counseling and standardized nurse-led stratified transitional nursing interventions. Methods: A single-center prospective cohort study enrolled 682 hospitalized lung cancer patients. Baseline demographic, socioeconomic, clinical, and patient-reported data (resilience, social support, fear of progression, symptom burden, self-efficacy) were collected. financial toxicity was assessed via the COST-PROM at 6 months post-discharge (score ≤ 25 defined as financial toxicity). Multivariable logistic regression was used to build the model, with ROC curve, calibration test, calibration slope, calibration intercept, optimism, shrinkage factor, Decision Curve Analysis, and 500-time Bootstrap resampling internal validation. Results: The 6-month post-discharge financial toxicity incidence was 76.2%. Annual household income, long-term residence, immunotherapy, self-efficacy, resilience, and fear of progression were independent predictors ( Conclusion: Lung cancer patients/survivors suffer from substantial financial toxicity within 6 months after hospital discharge, with household economic status, residential location, treatment modality, and diverse psychosocial coping factors serving as critical joint predictors of financial toxicity risk. The newly constructed prediction model underwent rigorous 500-time Bootstrap internal validation and demonstrated favorable discrimination, calibration, stability and overall predictive efficacy. This model enables clinicians and nurses to identify patients at high risk of financial toxicity before discharge, conduct early financial toxicity assessment, provide preliminary guidance on healthcare costs and insurance information, and coordinate tiered transitional care interventions through multidisciplinary collaboration to address cancer-related financial distress. Nevertheless, external validation remains essential before formal clinical implementation of the model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.